Home Featured Page 72

Featured

Latest

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Reflecting on Psychedelics in 2023

PT478 – Holotropic Breathwork as a Stepping Stone, Complementary Therapy, and...

PT477 – Oregon Measure 109: The Possibilities of Service Centers &...

Psychedelic Bulletin #153: MindMed Scraps Microdosing Program; Eagerly Anticipated Ibogaine Study...

Our Top 10 Psychedelics Articles in 2023

Natural Medicine Advisory Bulletin #7: December 2023

PT476 – Reinventing Organizations, Lessons From Burning Man, and Batman &...

The Obscure Advisory Panel Blocking Dozens of Psychedelic Studies in California

PT475 – End-of-Life Care and Psychedelics: The Role of a Death...

Pα+ Psychedelic Patent Analysis (November 2023)

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Reflecting on Psychedelics in 2023

PT478 – Holotropic Breathwork as a Stepping Stone, Complementary Therapy, and...

PT477 – Oregon Measure 109: The Possibilities of Service Centers &...

Psychedelic Bulletin #153: MindMed Scraps Microdosing Program; Eagerly Anticipated Ibogaine Study...

Our Top 10 Psychedelics Articles in 2023

Natural Medicine Advisory Bulletin #7: December 2023

PT476 – Reinventing Organizations, Lessons From Burning Man, and Batman &...

The Obscure Advisory Panel Blocking Dozens of Psychedelic Studies in California

PT475 – End-of-Life Care and Psychedelics: The Role of a Death...

Pα+ Psychedelic Patent Analysis (November 2023)

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY